Improving Representation in Clinical Trials and Research
Improving Representation in Clinical Trials and Research
复制标题
提高临床试验和研究的代表性
DOI：
--
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Kirsten Bibbins
中科院分区：
文献类型：
--
作者：
Kirsten Bibbins
美国长期以来对临床研究进行了大量投资，目的是改善我国的健康和福祉。毫无疑问，这些投资为治疗和预防疾病以及延长人类寿命做出了重大贡献。然而，临床研究面临着一个严重的缺陷。目前，大量美国人口以及那些经常面临最大健康挑战的人不太能够从这些发现中受益，因为他们在临床研究中没有得到充分的体现。尽管在临床试验和临床研究中白人女性的代表性方面取得了进展，但在过去三十年中，在增加种族和少数族裔群体的参与方面却进展甚微。这种代表性不足加剧了健康差距，给代表性不足的群体和国家带来严重后果。
The United States has long made substantial investments in clinical research with the goal of improving the health and well-being of our nation. There is no doubt that these investments have contributed significantly to treating and preventing disease and extending human life. Nevertheless, clinical research faces a critical shortcoming. Currently, large swaths of the U.S. population, and those that often face the greatest health challenges, are less able to benefit from these discoveries because they are not adequately represented in clinical research studies. While progress has been made with representation of white women in clinical trials and clinical research, there has been little progress in the last three decades to increase participation of racial and ethnic minority population groups. This underrepresentation is compounding health disparities, with serious consequences for underrepresented groups and for the nation.